Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dabrowski, M.
Right arrow Articles by Wahl, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dabrowski, M.
Right arrow Articles by Wahl, P.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:1896-1906, 2002
© 2002 by the American Diabetes Association, Inc.

The Novel Diazoxide Analog 3-Isopropylamino-7-Methoxy-4H-1,2,4-Benzothiadiazine 1,1-Dioxide Is a Selective Kir6.2/SUR1 Channel Opener

Michael Dabrowski1, Frances M. Ashcroft2, Rebecca Ashfield2, Philippe Lebrun3, Bernard Pirotte4, Jan Egebjerg5, John Bondo Hansen1, and Philip Wahl1

1 Research & Development, Novo Nordisk, Malov, Denmark
2 University Laboratory of Physiology, Oxford, U.K
3 Laboratory of Pharmacology, Faculty of Medicine, Free University of Brussels, Brussels, Belgium
4 Department of Medicinal Chemistry, Institute of Pharmacy, University of Liege, Liege, Belgium
5 Institute of Molecular and Structural Biology, Aarhus University, Aarhus, Denmark

ATP-sensitive K+ (KATP) channels are activated by a diverse group of compounds known as potassium channel openers (PCOs). Here, we report functional studies of the Kir6.2/SUR1 Selective PCO 3-isopropylamino-7-methoxy-4H-1,2,4-benzothiadiazine 1,1-dioxide (NNC 55-9216). We recorded cloned KATP channel currents from inside-out patches excised from Xenopus laevis oocytes heterologously expressing Kir6.2/SUR1, Kir6.2/SUR2A, or Kir6.2/SUR2B, corresponding to the ß-cell, cardiac, and smooth muscle types of the KATP channel. NNC 55-9216 reversibly activated Kir6.2/SUR1 currents (EC50 = 16 µmol/l). This activation was dependent on intracellular MgATP and was abolished by mutation of a single residue in the Walker A motifs of either nucleotide-binding domain of SUR1. The drug had no effect on Kir6.2/SUR2A or Kir6.2/SUR2B currents. We therefore used chimeras of SUR1 and SUR2A to identify regions of SUR1 involved in the response to NNC 55-9216. Activation was completely abolished and significantly reduced by swapping transmembrane domains 8–11. The reverse chimera consisting of SUR2A with transmembrane domains 8–11 and NBD2 consisting SUR1 was activated by NNC 55-9216, indicating that these SUR1 regions are important for drug activation. [3H]glibenclamide binding to membranes from HEK293 cells transfected with SUR1 was displaced by NNC 55-9216 (IC50 = 105 µmol/l), and this effect was impaired when NBD2 of SUR1 was replaced by that of SUR2A. These results suggest NNC 55-9216 is a SUR1-selective PCO that requires structural determinants, which differ from those needed for activation of the KATP channel by pinacidil and cromakalim. The high selectivity of NNC 55-9216 may prove to be useful for studies of the molecular mechanism of PCO action.



Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
B. Ng, Y. Kang, C. L. Elias, Y. He, H. Xie, J. B. Hansen, P. Wahl, and H. Y. Gaisano
The Actions of a Novel Potent Islet {beta}-Cell Specific ATP-Sensitive K+ Channel Opener Can Be Modulated by Syntaxin-1A Acting on Sulfonylurea Receptor 1
Diabetes, August 1, 2007; 56(8): 2124 - 2134.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
B. Raju and P. E. Cryer
Mechanism, temporal patterns, and magnitudes of the metabolic responses to the KATP channel agonist diazoxide
Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E80 - E85.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. Bryan, W. H. Vila-Carriles, G. Zhao, A. P. Babenko, and L. Aguilar-Bryan
Toward Linking Structure With Function in ATP-Sensitive K+ Channels
Diabetes, December 1, 2004; 53(suppl_3): S104 - S112.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. Hambrock, T. Kayar, D. Stumpp, and H. Osswald
Effect of Two Amino Acids in TM17 of Sulfonylurea Receptor SUR1 on the Binding of ATP-Sensitive K+ Channel Modulators
Diabetes, December 1, 2004; 53(suppl_3): S128 - S134.
[Abstract] [Full Text] [PDF]


Home page
J Biomol ScreenHome page
P. Arkhammar, P. Wahl, B. Gerlach, T. Fremming, and J. B. Hansen
Establishment and Application of in Vitro Membrane Potential Assays in Cell Lines with Endogenous or Recombinant Expression of ATP-Sensitive Potassium Channels (Kir6.2/SUR1) Using a Fluorescent Probe Kit
J Biomol Screen, August 1, 2004; 9(5): 382 - 390.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. A. Ritzel, J. B. Hansen, J. D. Veldhuis, and P. C. Butler
Induction of {beta}-Cell Rest by a Kir6.2/SUR1-Selective KATP-Channel Opener Preserves {beta}-Cell Insulin Stores and Insulin Secretion in Human Islets Cultured at High (11 mM) Glucose
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 795 - 805.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. J. DUNNE, K. E. COSGROVE, R. M. SHEPHERD, A. AYNSLEY-GREEN, and K. J. LINDLEY
Hyperinsulinism in Infancy: From Basic Science to Clinical Disease
Physiol Rev, January 1, 2004; 84(1): 239 - 275.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.